<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-02360854</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-24T19:41:11+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Monalizumab: inhibiting the novel immune checkpoint NKG2A</title>
            <author role="aut">
              <persName>
                <forename type="first">Thorbald</forename>
                <forename type="middle">Van</forename>
                <surname>Hall</surname>
              </persName>
              <idno type="halauthorid">1710805-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Pascale</forename>
                <surname>Andre</surname>
              </persName>
              <idno type="halauthorid">1205930-0</idno>
              <affiliation ref="#struct-111290"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Amir</forename>
                <surname>Horowitz</surname>
              </persName>
              <idno type="halauthorid">1205851-0</idno>
              <affiliation ref="#struct-210682"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Dan Fu</forename>
                <surname>Ruan</surname>
              </persName>
              <idno type="halauthorid">1710806-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Linda</forename>
                <surname>Borst</surname>
              </persName>
              <idno type="halauthorid">1710807-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Robert</forename>
                <surname>Zerbib</surname>
              </persName>
              <idno type="halauthorid">1394422-0</idno>
              <affiliation ref="#struct-111290"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Emilie</forename>
                <surname>Narni-Mancinelli</surname>
              </persName>
              <idno type="idhal" notation="numeric">760223</idno>
              <idno type="halauthorid" notation="string">346589-760223</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-7001-1026</idno>
              <idno type="IDREF">https://www.idref.fr/128875666</idno>
              <affiliation ref="#struct-182245"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Sjoerd H.</forename>
                <forename type="middle">van Der</forename>
                <surname>Burg</surname>
              </persName>
              <idno type="halauthorid">1710808-0</idno>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Eric</forename>
                <surname>Vivier</surname>
              </persName>
              <email type="md5">5bfb77e73d4fd86616173673fdef6ee1</email>
              <email type="domain">ciml.univ-mrs.fr</email>
              <idno type="idhal" notation="string">eric-vivier</idno>
              <idno type="idhal" notation="numeric">17342</idno>
              <idno type="halauthorid" notation="string">32004-17342</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/F-8939-2010</idno>
              <idno type="ORCID">https://orcid.org/0000-0001-7022-8287</idno>
              <idno type="IDREF">https://www.idref.fr/076121712</idno>
              <idno type="GOOGLE SCHOLAR">https://scholar.google.fr/citations?user=NlmFOgMAAAAJ</idno>
              <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/F-8939-2010</idno>
              <affiliation ref="#struct-182245"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Julien</forename>
                <surname>Caugant</surname>
              </persName>
              <email type="md5">0ffac29988b2006107b39eecc74efc3b</email>
              <email type="domain">univ-amu.fr</email>
            </editor>
            <funder ref="#projanr-50664"/>
            <funder ref="#projeurop-712594"/>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2023-11-16 11:34:00</date>
              <date type="whenModified">2024-04-11 03:26:13</date>
              <date type="whenReleased">2023-11-17 14:30:42</date>
              <date type="whenProduced">2019</date>
              <date type="whenEndEmbargoed">2023-11-16</date>
              <ref type="file" target="https://hal.science/hal-02360854v1/document">
                <date notBefore="2023-11-16"/>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://hal.science/hal-02360854v1/file/40425_2019_Article_761.pdf" id="file-4288896-3741733">
                <date notBefore="2023-11-16"/>
              </ref>
              <ref type="externalLink" target="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798508"/>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="777481">
                <persName>
                  <forename>Julien</forename>
                  <surname>Caugant</surname>
                </persName>
                <email type="md5">0ffac29988b2006107b39eecc74efc3b</email>
                <email type="domain">univ-amu.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-02360854</idno>
            <idno type="halUri">https://hal.science/hal-02360854</idno>
            <idno type="halBibtex">hall:hal-02360854</idno>
            <idno type="halRefHtml">&lt;i&gt;Journal for Immunotherapy of Cancer&lt;/i&gt;, 2019, 7 (1), &lt;a target="_blank" href="https://dx.doi.org/10.1186/s40425-019-0761-3"&gt;&amp;#x27E8;10.1186/s40425-019-0761-3&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Journal for Immunotherapy of Cancer, 2019, 7 (1), &amp;#x27E8;10.1186/s40425-019-0761-3&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4288896-3741733"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="UNIV-AMU">Aix Marseille Université</idno>
            <idno type="stamp" n="OPENAIRE">OpenAIRE</idno>
            <idno type="stamp" n="CERCLE">Publications des lauréats des projets ERC financés sur le site Aix Marseille</idno>
            <idno type="stamp" n="ANR">ANR</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Monalizumab: inhibiting the novel immune checkpoint NKG2A</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Thorbald</forename>
                    <forename type="middle">Van</forename>
                    <surname>Hall</surname>
                  </persName>
                  <idno type="halauthorid">1710805-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Pascale</forename>
                    <surname>Andre</surname>
                  </persName>
                  <idno type="halauthorid">1205930-0</idno>
                  <affiliation ref="#struct-111290"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Amir</forename>
                    <surname>Horowitz</surname>
                  </persName>
                  <idno type="halauthorid">1205851-0</idno>
                  <affiliation ref="#struct-210682"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Dan Fu</forename>
                    <surname>Ruan</surname>
                  </persName>
                  <idno type="halauthorid">1710806-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Linda</forename>
                    <surname>Borst</surname>
                  </persName>
                  <idno type="halauthorid">1710807-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Robert</forename>
                    <surname>Zerbib</surname>
                  </persName>
                  <idno type="halauthorid">1394422-0</idno>
                  <affiliation ref="#struct-111290"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Emilie</forename>
                    <surname>Narni-Mancinelli</surname>
                  </persName>
                  <idno type="idhal" notation="numeric">760223</idno>
                  <idno type="halauthorid" notation="string">346589-760223</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-7001-1026</idno>
                  <idno type="IDREF">https://www.idref.fr/128875666</idno>
                  <affiliation ref="#struct-182245"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Sjoerd H.</forename>
                    <forename type="middle">van Der</forename>
                    <surname>Burg</surname>
                  </persName>
                  <idno type="halauthorid">1710808-0</idno>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Eric</forename>
                    <surname>Vivier</surname>
                  </persName>
                  <email type="md5">5bfb77e73d4fd86616173673fdef6ee1</email>
                  <email type="domain">ciml.univ-mrs.fr</email>
                  <idno type="idhal" notation="string">eric-vivier</idno>
                  <idno type="idhal" notation="numeric">17342</idno>
                  <idno type="halauthorid" notation="string">32004-17342</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/F-8939-2010</idno>
                  <idno type="ORCID">https://orcid.org/0000-0001-7022-8287</idno>
                  <idno type="IDREF">https://www.idref.fr/076121712</idno>
                  <idno type="GOOGLE SCHOLAR">https://scholar.google.fr/citations?user=NlmFOgMAAAAJ</idno>
                  <idno type="RESEARCHERID">http://www.researcherid.com/rid/http://www.researcherid.com/rid/F-8939-2010</idno>
                  <affiliation ref="#struct-182245"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">83973</idno>
                <idno type="issn">2051-1426</idno>
                <title level="j">Journal for Immunotherapy of Cancer</title>
                <imprint>
                  <publisher>BMJ Publishing Group </publisher>
                  <biblScope unit="volume">7</biblScope>
                  <biblScope unit="issue">1</biblScope>
                  <date type="datePub">2019</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1186/s40425-019-0761-3</idno>
              <idno type="pubmedcentral">PMC6798508</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <classCode scheme="halDomain" n="sdv.imm">Life Sciences [q-bio]/Immunology</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhibition signals on T cells. Recently, we published proof-of-concept results on a novel checkpoint inhibitor, NKG2A. This receptor is expressed on cytotoxic lymphocytes, including NK cells and subsets of activated CD8(+) T cells. Blocking antibodies to NKG2A unleashed the reactivity of these effector cells resulting in tumor control in multiple mouse models and an early clinical trial. Monalizumab is inhibiting this checkpoint in human beings and future clinical trials will have to reveal its potency in combination with other cancer treatment options.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="institution" xml:id="struct-111290" status="VALID">
          <idno type="ROR">https://ror.org/055wa9133</idno>
          <orgName>Innate Pharma</orgName>
          <desc>
            <address>
              <addrLine>117, Avenue de Luminy - BP 30191 13276 Marseille Cedex 09</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.innate-pharma.com/</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-210682" status="INCOMING">
          <orgName>Departments of Chemistry and of Structural Biology</orgName>
          <desc>
            <address>
              <addrLine>Stanford University, Stanford, CA 94305</addrLine>
              <country key="US"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-73500" type="direct"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-182245" status="VALID">
          <idno type="IdRef">150044909</idno>
          <idno type="RNSR">200017461J</idno>
          <idno type="ROR">03vyjkj45</idno>
          <orgName>Centre d'Immunologie de Marseille - Luminy</orgName>
          <orgName type="acronym">CIML</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>Parc scientifique et technologique de Luminy - 163, avenue de Luminy - Case 906 - 13288 Marseille cedex 09</addrLine>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation name="UM 2" active="#struct-198056" type="direct"/>
            <relation name="UMR_S 1104" active="#struct-303623" type="direct"/>
            <relation name="UMR7280" active="#struct-441569" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-73500" status="VALID">
          <idno type="ROR">https://ror.org/00f54p054</idno>
          <orgName>Stanford University</orgName>
          <desc>
            <address>
              <addrLine>450 Serra Mall, Stanford, CA 94305-2004</addrLine>
              <country key="US"/>
            </address>
            <ref type="url">https://www.stanford.edu/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-198056" status="VALID">
          <idno type="IdRef">15863621X</idno>
          <idno type="ISNI">0000 0001 2176 4817</idno>
          <idno type="ROR">https://ror.org/035xkbk20</idno>
          <orgName>Aix Marseille Université</orgName>
          <orgName type="acronym">AMU</orgName>
          <date type="start">2012-01-01</date>
          <desc>
            <address>
              <addrLine>Aix-Marseille UniversitéJardins du Pharo58 Boulevard Charles Livon13284 Marseille cedex 7</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.univ-amu.fr/</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
      </listOrg>
      <listOrg type="projects">
        <org type="anrProject" xml:id="projanr-50664" status="VALID">
          <idno type="anr">ANR-17-RHUS-0007</idno>
          <orgName>PIONEER</orgName>
          <desc>Precision Immuno-Oncology for advanced Non small cell lung cancer patients with PD-1 ICI Resistance</desc>
          <date type="start">2017</date>
        </org>
        <org type="europeanProject" xml:id="projeurop-712594" status="VALID">
          <idno type="number">694502</idno>
          <idno type="program">ERC-2015-AdG</idno>
          <idno type="call">ERC-2015-AdG</idno>
          <orgName>TILC</orgName>
          <desc>Targeting Innate Lymphoid Cells</desc>
          <date type="start">2017-01-01</date>
          <date type="end">2022-12-31</date>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>